Endologix
Irvine
About Endologix
Endologix develops and manufactures minimally invasive treatments for aortic disorders. Endologix's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $210.6M
- Funding stage: IPO
- Last round: Post-IPO Debt (Apr 2017)
- Ticker: nasdaq:ELGX
- Website: endologix.com
- Phone: +1 949-595-7327
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/endologix-173092 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.